Press Releases

Date Title and Summary Additional Formats
Toggle Summary Quotient Limited Reports Third Quarter Fiscal 2021 Results and Business Update
MosaiQ COVID-19 semi-quantitative antibody test CE marked Expanded MosaiQ IH microarray EU launch planned for fourth quarter CY2021 Sales of Alba by Quotient reagents exceed guidance Strong cash position in place to carry us into commercialization JERSEY, Channel Islands, Feb.
View HTML
Toggle Summary Quotient Limited to Report Third Quarter 2021 Financial Results and Host Conference Call
JERSEY, Channel Islands , Jan. 19, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ended December 31, 2020 will be released before market open on Monday, February 1, 2021 .
View HTML
Toggle Summary Quotient Limited Wins 2021 BIG Innovation Award
JERSEY, Channel Islands , Jan. 12, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced it has been named a winner in the prestigious 2021 BIG Innovation Awards presented by the Business Intelligence Group .
View HTML
Toggle Summary Quotient Limited Announces Departure of Chief Operating Officer
JERSEY, Channel Islands , Dec. 22, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that on December 21, 2020 , Ed Farrell delivered a notice of resignation from his position as the Company's Chief Operating Officer.
View HTML
Toggle Summary Quotient Limited Provides Status Update on the Initial SDS Microarray and MosaiQ Instrument for the US Market
JERSEY, Channel Islands , Dec. 10, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that it received a request from the U.S. Food and Drug Administration (FDA) for additional testing data regarding the 510(k) application
View HTML
Toggle Summary Quotient Limited Announces MosaiQ™ Expanded IH EU Field Trial Performance Data
JERSEY, Channel Islands , Nov. 30, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported preliminary EU field trial performance data for its MosaiQ Expanded Immunohematology (IH) Microarray.
View HTML
Toggle Summary Quotient Limited to Participate in Two Upcoming Conferences
JERSEY, Channel Islands , Nov. 09, 2020 (GLOBE NEWSWIRE) -- Quotient Limited  (NASDAQ: QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland , today announced that the Company will participate in two upcoming virtual investor conferences.
View HTML
Toggle Summary Quotient Limited Reports Second Quarter Fiscal 2021 Results and Business Update
FDA Emergency Use Authorization for the MosaiQ COVID-19 antibody test received FDA 510(k) clearance for Initial MosaiQ SDS microarray and MosaiQ instrument expected before the end of CY2020 European field trial for Expanded MosaiQ IH microarray progressing; on track for CE Mark submission in Q4
View HTML
Toggle Summary Quotient Limited to Report Second Quarter 2021 Financial Results and Host Conference Call
JERSEY, Channel Islands, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal second quarter ended September 30, 2020 will be released before market open on Monday, Nov 2, 2020 .
View HTML
Toggle Summary Quotient Limited Announces Receipt of U.S. FDA Emergency Use Authorization (EUA) for MosaiQ COVID-19 Antibody test
JERSEY, Channel Islands, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), headquartered in Eysins, Switzerland , today announced that on September 25, 2020 , the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Quotient's COVID-19 antibody
View HTML